ClinicalTrials.Veeva

Menu

TARGET Post-Approval Study (TARGET PAS)

Abbott logo

Abbott

Status

Completed

Conditions

Complex Regional Pain Syndrome (CRPS)

Treatments

Device: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Device: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)

Study type

Observational

Funder types

Industry

Identifiers

NCT02800863
SJM-CIP-10113

Details and patient eligibility

About

The purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the Axium and Proclaim Neurostimulator System for dorsal root ganglion (DRG) stimulation. The primary endpoint is the 12-month serious adverse event rate for permanent implants.

Full description

A maximum of 426 adult subjects with moderate to severe chronic, intractable, pain of the lower limbs due to CRPS types I and II will undergo a trial of the Axium or Proclaim Neurostimulator System across up to 45 study sites in the United States. Only subjects who report a 50% or greater reduction in overall pain intensity through direct patient-reported percentage of pain relief will receive the permanent implant. Subjects will then return to the office for follow-up at 1, 3, 6 and 12 months post-permanent implant.

Enrollment

426 patients

Sex

All

Ages

22 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject is male or female between ≥ 22 and ≤ 75 years of age.
  • Subject has moderate to severe chronic intractable pain of the lower limbs resulting from Complex Regional Pain Syndrome (CRPS) types I or II.
  • Subject has a baseline Visual Analogue Scale (VAS) of ≥ 60 mm for overall pain at the time of the baseline assessment.
  • Subject is willing and able to comply with the study requirements.
  • Subject is able to provide written informed consent.

Exclusion criteria

  • Subject has an active implantable medical device including but not limited to cardiac pacemakers and cardiac defibrillators.
  • Subject is currently involved in medically related litigation, including workers compensation.
  • Subject has a life expectancy of less than one year.
  • Subject is pregnant or of child bearing potential and not using adequate contraception as determined by the investigator.
  • Subject has, or plans to have, a spinal cord stimulation system or infusion pump system implanted.
  • Subject has, or plans to have, a peripheral nerve stimulation system (PNS) or peripheral nerve field stimulation system (PNfS) implanted.
  • Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the implant procedure and/or recovery from the implant procedure or could complicate the required procedures and evaluations of the study in the judgment of the investigator.

Trial design

426 participants in 1 patient group

Dorsal Root Ganglion (DRG) Stimulation
Treatment:
Device: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)
Device: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)

Trial documents
2

Trial contacts and locations

44

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems